Analysis and Commentary STEVEN GROSSMAN 5/8/21 Analysis and Commentary STEVEN GROSSMAN 5/8/21 FDA Priorities for FY 22 Read More Analysis and Commentary STEVEN GROSSMAN 2/5/21 Analysis and Commentary STEVEN GROSSMAN 2/5/21 Alliance's "Ask" for FY 22: Member Input Is Requested Read More Analysis and Commentary STEVEN GROSSMAN 10/24/20 Analysis and Commentary STEVEN GROSSMAN 10/24/20 FY 21, FY 22 Appropriations and CDER Priorities Read More Analysis and Commentary STEVEN GROSSMAN 8/7/20 Analysis and Commentary STEVEN GROSSMAN 8/7/20 CDER Priorities: During the Pandemic and for 2021 Read More Advocacy at a Glance STEVEN GROSSMAN 7/26/20 Advocacy at a Glance STEVEN GROSSMAN 7/26/20 House Appropriations Minibus Containing FY 21 Ag/FDA Funding Advances Read More Analysis and Commentary STEVEN GROSSMAN 1/25/20 Analysis and Commentary STEVEN GROSSMAN 1/25/20 Alliance Learns About CBER Priorities for 2020 and Beyond Read More Advocacy at a Glance STEVEN GROSSMAN 8/2/19 Advocacy at a Glance STEVEN GROSSMAN 8/2/19 Budget Deal Passes Senate, President Agrees to Sign Read More Analysis and Commentary STEVEN GROSSMAN 8/31/18 Analysis and Commentary STEVEN GROSSMAN 8/31/18 On the Physical Capabilities of a Lame Duck Read More Analysis and Commentary STEVEN GROSSMAN 4/13/18 Analysis and Commentary STEVEN GROSSMAN 4/13/18 CBER Today and Tomorrow: Challenges and Opportunities Read More Analysis and Commentary STEVEN GROSSMAN 3/16/18 Analysis and Commentary STEVEN GROSSMAN 3/16/18 Key CDER Priorities Need Funding Too Read More Advocacy at a Glance STEVEN GROSSMAN 3/16/18 Advocacy at a Glance STEVEN GROSSMAN 3/16/18 Unclear Whether Congress Can Avoid Brinksmanship and more Read More Analysis and Commentary STEVEN GROSSMAN 3/11/18 Analysis and Commentary STEVEN GROSSMAN 3/11/18 Game-Changing Medical Device Priorities Need Funding Read More Advocacy at a Glance STEVEN GROSSMAN 3/11/18 Advocacy at a Glance STEVEN GROSSMAN 3/11/18 FDA’s Breakthrough Device Program Featured and more Read More Analysis and Commentary STEVEN GROSSMAN 8/11/17 Analysis and Commentary STEVEN GROSSMAN 8/11/17 It's Going to Get Tougher From Here Read More Advocacy at a Glance STEVEN GROSSMAN 5/19/17 Advocacy at a Glance STEVEN GROSSMAN 5/19/17 New FDA Commissioner Scott Gottlieb Read More Advocacy at a Glance STEVEN GROSSMAN 1/13/17 Advocacy at a Glance STEVEN GROSSMAN 1/13/17 Sequester May Follow April 28 Expiration of FY 17 CR Read More Advocacy at a Glance STEVEN GROSSMAN 7/22/16 Advocacy at a Glance STEVEN GROSSMAN 7/22/16 FDA Issues Strategic Plan for Food Safety and Veterinary Medicine Read More Advocacy at a Glance STEVEN GROSSMAN 7/15/16 Advocacy at a Glance STEVEN GROSSMAN 7/15/16 Congress’ Summer Adjournment; Back in September Read More Advocacy at a Glance STEVEN GROSSMAN 7/8/16 Advocacy at a Glance STEVEN GROSSMAN 7/8/16 One Week until Congress’ Summer Adjournment Read More Analysis and Commentary STEVEN GROSSMAN 4/22/16 Analysis and Commentary STEVEN GROSSMAN 4/22/16 The Start of the Califf Era Read More Older Posts
Analysis and Commentary STEVEN GROSSMAN 5/8/21 Analysis and Commentary STEVEN GROSSMAN 5/8/21 FDA Priorities for FY 22 Read More
Analysis and Commentary STEVEN GROSSMAN 2/5/21 Analysis and Commentary STEVEN GROSSMAN 2/5/21 Alliance's "Ask" for FY 22: Member Input Is Requested Read More
Analysis and Commentary STEVEN GROSSMAN 10/24/20 Analysis and Commentary STEVEN GROSSMAN 10/24/20 FY 21, FY 22 Appropriations and CDER Priorities Read More
Analysis and Commentary STEVEN GROSSMAN 8/7/20 Analysis and Commentary STEVEN GROSSMAN 8/7/20 CDER Priorities: During the Pandemic and for 2021 Read More
Advocacy at a Glance STEVEN GROSSMAN 7/26/20 Advocacy at a Glance STEVEN GROSSMAN 7/26/20 House Appropriations Minibus Containing FY 21 Ag/FDA Funding Advances Read More
Analysis and Commentary STEVEN GROSSMAN 1/25/20 Analysis and Commentary STEVEN GROSSMAN 1/25/20 Alliance Learns About CBER Priorities for 2020 and Beyond Read More
Advocacy at a Glance STEVEN GROSSMAN 8/2/19 Advocacy at a Glance STEVEN GROSSMAN 8/2/19 Budget Deal Passes Senate, President Agrees to Sign Read More
Analysis and Commentary STEVEN GROSSMAN 8/31/18 Analysis and Commentary STEVEN GROSSMAN 8/31/18 On the Physical Capabilities of a Lame Duck Read More
Analysis and Commentary STEVEN GROSSMAN 4/13/18 Analysis and Commentary STEVEN GROSSMAN 4/13/18 CBER Today and Tomorrow: Challenges and Opportunities Read More
Analysis and Commentary STEVEN GROSSMAN 3/16/18 Analysis and Commentary STEVEN GROSSMAN 3/16/18 Key CDER Priorities Need Funding Too Read More
Advocacy at a Glance STEVEN GROSSMAN 3/16/18 Advocacy at a Glance STEVEN GROSSMAN 3/16/18 Unclear Whether Congress Can Avoid Brinksmanship and more Read More
Analysis and Commentary STEVEN GROSSMAN 3/11/18 Analysis and Commentary STEVEN GROSSMAN 3/11/18 Game-Changing Medical Device Priorities Need Funding Read More
Advocacy at a Glance STEVEN GROSSMAN 3/11/18 Advocacy at a Glance STEVEN GROSSMAN 3/11/18 FDA’s Breakthrough Device Program Featured and more Read More
Analysis and Commentary STEVEN GROSSMAN 8/11/17 Analysis and Commentary STEVEN GROSSMAN 8/11/17 It's Going to Get Tougher From Here Read More
Advocacy at a Glance STEVEN GROSSMAN 5/19/17 Advocacy at a Glance STEVEN GROSSMAN 5/19/17 New FDA Commissioner Scott Gottlieb Read More
Advocacy at a Glance STEVEN GROSSMAN 1/13/17 Advocacy at a Glance STEVEN GROSSMAN 1/13/17 Sequester May Follow April 28 Expiration of FY 17 CR Read More
Advocacy at a Glance STEVEN GROSSMAN 7/22/16 Advocacy at a Glance STEVEN GROSSMAN 7/22/16 FDA Issues Strategic Plan for Food Safety and Veterinary Medicine Read More
Advocacy at a Glance STEVEN GROSSMAN 7/15/16 Advocacy at a Glance STEVEN GROSSMAN 7/15/16 Congress’ Summer Adjournment; Back in September Read More
Advocacy at a Glance STEVEN GROSSMAN 7/8/16 Advocacy at a Glance STEVEN GROSSMAN 7/8/16 One Week until Congress’ Summer Adjournment Read More
Analysis and Commentary STEVEN GROSSMAN 4/22/16 Analysis and Commentary STEVEN GROSSMAN 4/22/16 The Start of the Califf Era Read More
